Who is eligible for clinical trial NCT04612751?

Participants must meet protocol criteria for Advanced or Metastatic NSCLC. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT04612751 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-24

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (NCT04612751)

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This study will assess safety, tolerability, and treatment activity of datopotamab deruxtecan (Dato-DXd) in combination with immunotherapy with or without carboplatin in participants with advanced or metastatic non-small cell lung cancer (NSCLC).

Who can join: Review the eligibility criteria below.

Location: Research Site — La Jolla, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (42 Sites)

Showing the first 25 of 42 sites.

Research Site — La Jolla, California
Research Site — Santa Ana, California
Research Site — St Louis, Missouri
Research Site — Hackensack, New Jersey
Research Site — Cleveland, Ohio
Research Site — Philadelphia, Pennsylvania
Research Site — Dallas, Texas
Research Site — Houston, Texas
Research Site — San Antonio, Texas
Research Site — Fairfax, Virginia
Research Site — Hasselt,
Research Site — Roeselare,
Research Site — Aviano,
Research Site — Meldola,
Research Site — Orbassano,
Research Site — Roma,
Research Site — Kōtoku,
Research Site — Sunto-gun,
Research Site — Yokohama,
Research Site — Gdansk,
Research Site — Lodz,
Research Site — Lublin,
Research Site — Warsaw,
Research Site — A Coruña,
Research Site — Badalona,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced or Metastatic NSCLC

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) — Scottsdale, Arizona

Explore by condition: All Advanced or Metastatic NSCLC clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗